Incyte, Genmab to Test Drug Combination for Colorectal Cancer

Incyte (INCY) will present new data on its hematology portfolio at ASH 2026, including updates on INCA033989 for myelofibrosis and essential thrombocythemia, and latarcibart for von Willebrand disease. Over 30 abstracts will be shared, with an investor event scheduled for December 12, 2026.

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.

Incyte (INCY) reported Q3 revenue of $1.56B, up 14% YoY, with net sales also rising 14% to $1.32B. All products grew, led by Jakafi and OPZELURA. The company raised full-year sales guidance to $5.21B-$5.3B. Management highlighted a larger late-stage pipeline but noted risks including higher expenses and pricing pressure on Jakafi.

Oppenheimer upgraded Incyte to Outperform, citing growth prospects beyond Jakafi's 2029 exclusivity loss. The firm set a $144 price target, 23% above Incyte's Oct. 29 closing price.

Incyte Corporation (INCY) reported Q3 2026 revenue of $1.56 billion, up 14% YoY, beating estimates. Full-year guidance was raised to $5.26 billion, though still below analyst expectations. Adjusted EPS loss was $3.60, better than expected. Operating margin declined to -45.5% due to R&D expenses. Management highlighted growth in OPZELURA and hematology-oncology brands, with continued investment in pipeline and acquisitions pressuring margins.

Oppenheimer upgraded Incyte (INCY) to outperform, citing growth potential beyond Jakafi's exclusivity. The firm set a $144 price target, implying ~23% upside from Oct. 29 close, according to the analyst.